Αρχική World News Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based COVID-19...

Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based COVID-19 Vaccine

In a study conducted by Dr Romain Palich of the Medical Oncology department, Pitié-Salpêtrière hospital in Paris, France and colleagues almost half patients with cancer showed no anti-spike antibody response after a first injection of BNT162b2 (Pfizer-BioNTech) vaccine, and this low seroconversion rate was much worse in elderly patients and in those under chemotherapy. Moreover, even in patients with seroconversion, the level of antibody response was lower than expected. Findings from the study on antibody response 4 weeks after the first injection of the BNT162b2 vaccine in patients with cancer and healthcare workers as the control population were published on 28 April 2021 in the Annals of Oncology.

Patients with cancer on active treatment or who were treated in last two years and healthcare workers who received vaccine between 17 February 2021 and 18 March 2021 at the Pitié-Salpêtrière hospital were included in this analysis. Titration of antibodies was done just before the second injection of BNT162b2 vaccine.

The antibodies were measured in 110 patients with cancer and 25 healthcare workers. In patients with cancer who did not have COVID-19 before vaccination, the seroconversion rate was only 55% versus 100% in healthcare workers. Titers of antibodies were significantly higher in healthcare workers when compared with seropositive patients with cancer, in particular 680 versus 315 UA/mL (p = 0.04).

Gender, cancer locations and metastatic status were similar in patients with cancer with seroconversion and non-seroconversion.

After adjustment for potential confounders, age over 65 (odds-ratio [OR] 3.58, 95% confidence interval [CI] 1.40-9.15, p = 0.008) and treatment with chemotherapy (OR 4.34, 95% CI 1.67-11.30, p = 0.003) were two factors that have strongly associated with no seroconversion.

No symptomatic COVID-19 occurred between the two vaccine injections neither in patients with cancer nor healthcare workers.

The study team argued for not extending the 21-day period between the two vaccine injections in patients with cancer and for performing serological monitoring to assess antibody response in this population. They also recommended COVID-19 vaccination among family and friendship circles.

This study was approved by the Commission Nationale de l’Informatique et des Libertés.

Reference

Palich R, Veyri M, Marot S, et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Annals of Oncology; Published online 28 April 2021; DOI: https://doi.org/10.1016/j.annonc.2021.04.020

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...